BioD LLC to Display Range of Biologic Products at AAOS

Memphis, Tenn.-based BioD LLC, a biomedical company that makes biologic orthopedic products derived from placental tissue, will be exhibiting at the American Academy of Orthopaedic Surgeons (AAOS) 80th Annual Meeting in Chicago, Ill., held March 19-23. At the conference, the company will introduce its BioDGenesis Micronized Tissue Matrix. Also on display will be BioD’s entire placental tissue-based product portfolio including BioDfactor, BioDfence (pictured left), and AmnioExcel.

BioDfactor is a liquid wound covering product for use in vivo to fill soft tissue defects. BioDfence is an in vivo wound covering designed to provide a physical barrier to protect tendons and nerves at the surgical site. AmnioExcel is a extracellular wound covering derived from amnion.

The BioDGenesis Micronized Tissue Matrix is a cryopreserved injectable allograft derived from human placental tissues for use as a wound covering in the treatment of localized areas of joint inflammation or soft tissue injury. The allograft is primarily used in sports medicine applications, but BioDGenesis can reportedly be used to cover and protect any wound or localized area of inflammation and to provide a natural scaffold that facilitates the migration and proliferation of the patient’s own cells to the site of injury.

“We are excited to bring our advanced tissue processing technology to the AAOS,” said President and CEO Greg Brophy. “We believe the versatility and regenerative potential of our placental-derived products is an ideal solution for the treatment of many sports medicine injuries. This meeting is an excellent forum for BioD to present our novel biologic products to the orthopedic medical community.”

BioD has more than 25 patents and provisional patents filed in connection with its proprietary processing techniques and the clinical use of its products, according to Brophy. BioD’s goal is to develop a “complete line of novel tissue-based products that will enhance the quality of patient care in a broad range of clinical applications,” the CEO added.

BioD’s research and development efforts are focused on the regenerative potential of amnion and other placental tissues, which have a unique biologic structure with their rich source of undifferentiated stem cells and the unique immune privilege that characterizes their function in the body. The company recovers tissue from live, healthy donors during childbirth.

Editor’s note: If you are attending AAOS and want to learn more, the company is at booth number 114.

Photo of BioDfence courtesy of Icon Health Solutions.